Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Anal Carcinoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(22)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Anal Carcinoma
No biomarker
Anal Carcinoma
MIXE
Sensitive: A2 - Guideline
MIXE
Sensitive
:
A2
MIXE
Sensitive: A2 - Guideline
MIXE
Sensitive
:
A2
No biomarker
Anal Carcinoma
No biomarker
Anal Carcinoma
TPF
Sensitive: A2 - Guideline
TPF
Sensitive
:
A2
TPF
Sensitive: A2 - Guideline
TPF
Sensitive
:
A2
No biomarker
Anal Carcinoma
No biomarker
Anal Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Anal Carcinoma
No biomarker
Anal Carcinoma
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
No biomarker
Anal Carcinoma
No biomarker
Anal Carcinoma
FOLFOX
Sensitive: A2 - Guideline
FOLFOX
Sensitive
:
A2
FOLFOX
Sensitive: A2 - Guideline
FOLFOX
Sensitive
:
A2
No biomarker
Anal Carcinoma
No biomarker
Anal Carcinoma
carboplatin + paclitaxel
Sensitive: A2 - Guideline
carboplatin + paclitaxel
Sensitive
:
A2
carboplatin + paclitaxel
Sensitive: A2 - Guideline
carboplatin + paclitaxel
Sensitive
:
A2
No biomarker
Anal Carcinoma
No biomarker
Anal Carcinoma
FOLFCIS
Sensitive: A2 - Guideline
FOLFCIS
Sensitive
:
A2
FOLFCIS
Sensitive: A2 - Guideline
FOLFCIS
Sensitive
:
A2
No biomarker
Anal Carcinoma
No biomarker
Anal Carcinoma
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
cisplatin + 5-fluorouracil
Sensitive
:
A2
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
cisplatin + 5-fluorouracil
Sensitive
:
A2
No biomarker
Anal Carcinoma
No biomarker
Anal Carcinoma
mFOLFOX6
Sensitive: A2 - Guideline
mFOLFOX6
Sensitive
:
A2
mFOLFOX6
Sensitive: A2 - Guideline
mFOLFOX6
Sensitive
:
A2
No biomarker
Anal Carcinoma
No biomarker
Anal Carcinoma
capecitabine + mitomycin
Sensitive: A2 - Guideline
capecitabine + mitomycin
Sensitive
:
A2
capecitabine + mitomycin
Sensitive: A2 - Guideline
capecitabine + mitomycin
Sensitive
:
A2
No biomarker
Anal Carcinoma
No biomarker
Anal Carcinoma
5-fluorouracil + mitomycin
Sensitive: A2 - Guideline
5-fluorouracil + mitomycin
Sensitive
:
A2
5-fluorouracil + mitomycin
Sensitive: A2 - Guideline
5-fluorouracil + mitomycin
Sensitive
:
A2
No biomarker
Anal Carcinoma
No biomarker
Anal Carcinoma
DCF
Sensitive: A2 - Guideline
DCF
Sensitive
:
A2
DCF
Sensitive: A2 - Guideline
DCF
Sensitive
:
A2
No biomarker
Anal Carcinoma
No biomarker
Anal Carcinoma
cisplatin + docetaxel
Sensitive: A2 - Guideline
cisplatin + docetaxel
Sensitive
:
A2
cisplatin + docetaxel
Sensitive: A2 - Guideline
cisplatin + docetaxel
Sensitive
:
A2
No biomarker
Anal Carcinoma
No biomarker
Anal Carcinoma
cisplatin + carboplatin
Sensitive: A2 - Guideline
cisplatin + carboplatin
Sensitive
:
A2
cisplatin + carboplatin
Sensitive: A2 - Guideline
cisplatin + carboplatin
Sensitive
:
A2
No biomarker
Anal Carcinoma
No biomarker
Anal Carcinoma
cisplatin + 5-fluorouracil + capecitabine
Sensitive: A2 - Guideline
cisplatin + 5-fluorouracil + capecitabine
Sensitive
:
A2
cisplatin + 5-fluorouracil + capecitabine
Sensitive: A2 - Guideline
cisplatin + 5-fluorouracil + capecitabine
Sensitive
:
A2
PD-L1 expression
Anal Carcinoma
PD-L1 expression
Anal Carcinoma
pembrolizumab
Sensitive: C1 - Off-label
pembrolizumab
Sensitive
:
C1
pembrolizumab
Sensitive: C1 - Off-label
pembrolizumab
Sensitive
:
C1
MSI-H/dMMR
Anal Carcinoma
MSI-H/dMMR
Anal Carcinoma
nivolumab
Sensitive: C1 - Off-label
nivolumab
Sensitive
:
C1
nivolumab
Sensitive: C1 - Off-label
nivolumab
Sensitive
:
C1
PD-L1 overexpression + TMB-H
Anal Carcinoma
PD-L1 overexpression + TMB-H
Anal Carcinoma
EGFR inhibitor + Immunotherapy
Sensitive: C3 – Early Trials
EGFR inhibitor + Immunotherapy
Sensitive
:
C3
EGFR inhibitor + Immunotherapy
Sensitive: C3 – Early Trials
EGFR inhibitor + Immunotherapy
Sensitive
:
C3
CD163 expression
Anal Carcinoma
CD163 expression
Anal Carcinoma
toripalimab-tpzi
Sensitive: C3 – Early Trials
toripalimab-tpzi
Sensitive
:
C3
toripalimab-tpzi
Sensitive: C3 – Early Trials
toripalimab-tpzi
Sensitive
:
C3
CD4 expression
Anal Carcinoma
CD4 expression
Anal Carcinoma
toripalimab-tpzi
Sensitive: C3 – Early Trials
toripalimab-tpzi
Sensitive
:
C3
toripalimab-tpzi
Sensitive: C3 – Early Trials
toripalimab-tpzi
Sensitive
:
C3
PD-L1 expression
Anal Carcinoma
PD-L1 expression
Anal Carcinoma
toripalimab-tpzi
Sensitive: C3 – Early Trials
toripalimab-tpzi
Sensitive
:
C3
toripalimab-tpzi
Sensitive: C3 – Early Trials
toripalimab-tpzi
Sensitive
:
C3
PD-L1 amplification + PD-L2 amplification + TMB-H
Anal Carcinoma
PD-L1 amplification + PD-L2 amplification + TMB-H
Anal Carcinoma
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login